Dr. LoRusso on Personalized Medicine for Melanoma

Patricia M. LoRusso, DO
Published: Wednesday, Apr 15, 2015



Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.

All the patients on the trial have progressed on immunotherapy and are now in need of additional treatment. Currently, there are no targeted therapies approved by the FDA for this subset of patients.

By using genotyping, individualized treatments are selected for each of theses patient based on their tumor, explains LoRusso. This approach is predicted to be more effective than the standard of care.


Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.

All the patients on the trial have progressed on immunotherapy and are now in need of additional treatment. Currently, there are no targeted therapies approved by the FDA for this subset of patients.

By using genotyping, individualized treatments are selected for each of theses patient based on their tumor, explains LoRusso. This approach is predicted to be more effective than the standard of care.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x